Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)
Evercore ISI analyst Gavin Clark-Gartner resumed coverage with a Buy rating on BioCryst yesterday and set a price target of $17.00. The company’s shares closed yesterday at $7.26.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Clark-Gartner is a 5-star analyst with an average return of 25.0% and a 61.36% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Viridian Therapeutics, and Ascendis Pharma.
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $21.50.
Based on BioCryst’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.4 million and a net profit of $12.9 million. In comparison, last year the company earned a revenue of $117.09 million and had a GAAP net loss of $14.03 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Most recently, in December 2025, Alane Barnes, the CLO of BCRX sold 50,906.00 shares for a total of $367,032.26.
Read More on BCRX:
